- Innovating as a global leader in cryoablation
technologies, with 42 patents issued and allowed
- Cryogenic flow control enhances the efficacy and
precision of cryoablation procedures
CAESAREA, Israel, March 12,
2024 /PRNewswire/ -- IceCure Medical
Ltd. (Nasdaq: ICCM) ("IceCure" or the
"Company"), developer of the ProSense® System, a minimally-invasive
cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced it has received a Notice of Allowance from the Japan
Patent Office (the "JPO") for its patent application titled
"Cryogen Flow Control". Once granted, the patent will be in effect
until 2042. A patent for this invention is pending approval in
European Union, the U.S., and other major markets.
Precise temperature control is crucial for efficacy and tissue
safety in cryoablation procedures. Cryogenic flow control achieves
this by utilizing sensor data to regulate the flow of cryogens,
ensuring the desired temperature is reached and maintained at the
distal tip of catheters and probes. This optimized cryogenic
delivery enhances treatment effectiveness in cryoablation
procedures. Advanced cryogen flow control systems may also offer
functionalities, such as navigation and mapping support within the
patient's anatomy, and be incorporated into a wide range of
cryosurgical tools.
"We believe that cryogen flow control will be instrumental in
enabling practitioners to perform accurate navigation and
cryo-mapping to achieve cryoablation efficiency and expand
cryoablation treatment to more clinical applications in the
future," stated Eyal Shamir,
IceCure's Chief Executive Officer. "As a leader in cryoablation
technology worldwide, we continue to innovate and build our IP
portfolio. This Notice of Allowance in Japan further fortifies our position in an
important market, served in partnership with our in-country
distributor, Terumo."
About ProSense®
The ProSense® Cryoablation System provides a minimally invasive
treatment option to destroy tumors by freezing them. The system
uniquely harnesses the power of liquid nitrogen to create large
lethal zones for maximum efficacy in tumor destruction in benign
and cancerous lesions, including breast, kidney, lung, and
liver.
ProSense® enhances patient and provider value by accelerating
recovery, reducing pain, surgical risks, and complications. With
its easy, transportable design and liquid nitrogen utilization,
ProSense® opens that door to fast and convenient office-based
procedures for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, the Company uses
forward-looking statements when it discusses that advanced cryogen
flow control systems may also offer other and that the Company
believes that cryogen flow control will be instrumental in enabling
practitioners to perform accurate navigation and cryo-mapping, that
the Company is continuing to innovate and build its IP portfolio
and that this Notice of Allowance in Japan further fortifies the Company's position
in Japan. Historical results of scientific research and
clinical and preclinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions. Important factors that could cause actual
results, developments and business decisions to differ materially
from those anticipated in these forward-looking statements include,
among others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to
obtain additional funding; the Company's ability to market and sell
its products; legal and regulatory developments in the United States and other countries; the
Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain
or protect the validity of its patents and other intellectual
property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military
instability in the Middle East,
specifically in Israel; as well as
those factors set forth in the Risk Factors section of the
Company's Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the SEC
on March 29, 2023, and other
documents filed with or furnished to the SEC which are available on
the SEC's website, www.sec.gov. The Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-receives-notice-of-patent-allowance-in-japan-for-a-novel-cryogen-flow-control-to-optimize-patient-outcomes-302086612.html
SOURCE IceCure Medical